Kuan Arthur 4

What Happened

• Kuan Arthur, CEO of CG Oncology (CGON), was granted a derivative award covering 271,600 shares on April 15, 2026. The filing reports an acquisition price of $0.00 (derivative), indicating no cash was paid at grant. This is a grant of an equity-based compensation award (reported as an option/derivative), not a market purchase or sale.

Key Details

• Transaction date: 2026-04-15; Form 4 filed: 2026-04-16 (timely filing).
• Amount: 271,600 shares (derivative award) reported at $0.00 acquisition price.
• Vesting: 1/48th of the shares subject to the option vest monthly following April 15, 2026, contingent on continuous service through each vesting date (per footnote).
• Shares owned after transaction: Not disclosed in the provided filing excerpt.
• Filing status: No indication of a late filing in the provided data.

Context

• This was a compensation grant (an equity award/option), not a sale or purchase. Such grants are typical for executive compensation and do not represent an immediate market purchase or sale; value to the holder depends on future vesting and any exercise terms.
• For a full picture (strike price, any acceleration, or total ownership), consult the complete Form 4 and company disclosures.